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Editorial on the Research Topic
Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis
and Treatment
Tuberculosis (TB), is one of the top 10 causes of death worldwide (WHO). According to the last
Global TB report from the World Health Organization, 10 million persons were estimated to
have had TB in 2019 worldwide, causing about 1.6 million deaths. Tuberculosis has not only a
dramatic impact on the quality of life for the patients, but also has raised many socio-economic
issues at a community level, especially in medium and high burden regions, such as India, China,
and Indonesia.
In 2014,WHO adopted the “End TB strategy” which aimed to reduce TB deaths by 90% between
2015 and 2030, to prevent new cases by 80% during the same period and to decrease the socio-
economic impact of the disease at a family level. Even though tuberculosis global incidence has
decreased significantly, efforts still need to be made to reach these goals.
Non-tuberculous mycobacteria (NTM), in contrast to Mycobacterium tuberculosis, are bacteria
widely spread in the environment and can be found in a broad range of ecosystems such as soils
and water, including drinking water systems. NTM are opportunistic pathogens associated with
both pulmonary and extrapulmonary infections.
This Research Topic collected articles addressing: (i) TB and NTMs associated diseases,
diagnostic, control, and public health, (ii) mycobacterial genomics, (iii) and antimycobacterial
drugs and resistance.
Efforts have been made to present the latest technical and scientific approaches for resistance
prediction and mutation ranking in M. tuberculosis. This included the use of multi-label random
forest models from whole genome sequences to rank and identify important mutations for better
prediction of first-line drugs resistance (Kouchaki et al.). According to the major advances achieved
in the last years, diagnostic and epidemiological approaches based on genomics have dramatically
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increased. Whole genome sequencing (WGS) is widely used to
identify clusters of transmission of M. tuberculosis in different
settings like in Ghana, where WGS analysis was used to resolve
clusters and explored the spatial distribution of confirmed
recent transmission events (Asare et al.). WGS was useful in
detecting unsuspected outbreaks as well as to better understand
the dynamic of M. tuberculosis lineages (Outhred et al.).
Different approaches are now available for rapid and accurate
drug susceptibility testing including phenotypic and molecular
methods based on DNA sequencing. This latter approach has
shown its added value for early identification of resistance to
anti-TB drugs, including ethambutol (Li et al.; Wan et al.).
Finally, the study of M. tuberculosis wild-type MIC
distributions addressed the possibility of re-evaluating the
critical concentration of anti-TB drugs and pharmacodynamics
or optimizing the drug dosage (Dusthackeer et al.). In the
endeavor of TB treatment and anti-TB drugs discovery, a new
competitive inhibitor of D-alanine–D-alanine ligase A (DdlA)
(IMB-0283) that is more potent than the classical D-cycloserine
(DCS) has been identified via high-throughput screening (Meng
et al.). The MIC of IMB-0283 for the standard and clinical drug-
resistantM. tuberculosis strains ranged from 0.25 to 4.00µg/mL,
whereas that of DCS was 16µg/mL. This new inhibitor revealed
to have lower cytotoxicity and to be more efficacious in vivo
than DCS, a still important second line antituberculosis drug.
Alongside, and in view of the urgent need of more efficacious
and less toxic second line antituberculosis drugs, the potential
of the recently described cephalosporins, selectively active
against non-replicating Mycobacterium tuberculosis forms, has
been reported. Using alkyne analogs of these cephalosporins
and an activity-based protein profiling, over 30 new protein
binders were identified related to mycobacterial survival in
a non-replicative state and inhibiting the cell by collective
action on multiple targets (Lopez Quezada et al.). Improvement
of anti-TB regimen, including regimen for the treatment of
multidrug-resistant tuberculosis is paramount as such treatment
have been shown to have long-term effects on gut microbiota
(Wang et al.).
Regarding the treatment of NTM infections, a retrospective
analysis focusing on Mycobacterium abscessus pulmonary
infection reported that among 244 patients, only 110 patients
met the criteria for treatment, and the outcomes of treatment
were mostly unsatisfactory, particularly among patients suffering
from Mycobacterium abscessus subsp. abscessus lung disease
(Chen et al.). The administration of amikacin, imipenem,
linezolid, and tigecycline correlated with increased treatment
success. Genomics were also now established as a powerful
tool to refine and complete the systematics and classification
of NTMs as shown for the M. kansasii complex and subtypes
reclassified using a three-pronged computational strategy based
on the alignment fraction-average nucleotide identity, genome-
to-genome distance, and core-genome phylogeny combined with
five canonical taxonomic markers (16S rRNA, hsp65, rpoB, tuf
genes, and 16S-23S rRNA intergenic spacer region; Jagielski et
al.). A study on another clinical important NTM, the M. avium
complex (MAC) determined the impact of using two different
culture media used for MAC drug susceptibility testing. MIC
determination using the microdilution method for antibiotics
used in the treatment of MAC infections has a clear clinical
relevance and accuracy for determining the resistance levels
of this important group of NTM (Jaffré et al.). The raise
of the medical importance of NTM due to the increasing
number of immune-compromised hosts (solid organ transplant
recipients and oncologic patients among others) highlighted
the importance of a better understanding of the source of
contamination and measures to reduce exposure to these sources
(Norton et al.; Lecorche et al.).
Major advances have been made in the field of TB
and NTM relying on many new technological opportunities,
new approaches and new paradigms. This led to a better
understanding of these pathogens as well as in improvement
of patients care and disease control. Regarding patients care,
the importance of multidisciplinary approaches taking into
account medico-socio-economic considerations was highlighted
(Mazza-Stalder et al.; Pujol-Cruells and Vilaplana). Interestingly,
this Research Topic also highlighted the inhomogeneity of
practices among Europe for the management of TB (Méchaï
et al.). Efforts need to be intensified in parallel with increased
translational collaboration to guarantee the application and rapid
sharing of new discoveries.
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